Introduction {#s1}
============

Respiratory viruses represent the most common infections in children (Tregoning and Schwarze, [@B206]; Meissner, [@B145]; Kou et al., [@B124]). In healthy children, they usually cause upper respiratory tract infections (URTI) with a benign, self-limited course (Tregoning and Schwarze, [@B206]; Meissner, [@B145]). However, immunocompromised hosts, particularly those undergoing transplant are particularly vulnerable to severe infections (Whimbey et al., [@B223], [@B225]; Couch et al., [@B39]; Englund et al., [@B66], [@B61]; Englund, [@B62]; Kim et al., [@B118]; Campbell et al., [@B22]). Furthermore, the spectrum of immunocompromised patients has expanded over the past decade owing to prolonged survival of those with various malignancies and to advances in hematopoietic cell transplantation (HCT) (Englund, [@B62]; Englund et al., [@B61]; Fisher et al., [@B72]). As diagnostic test improve and virus are detected more rapidly, the burden of these infections and their clinical outcomes have been progressively recognized (Englund et al., [@B65], [@B66]; Englund, [@B62]). Although respiratory infections can be due to opportunistic infections, uncommon or atypical organisms, community respiratory virus are usually the cause of hospitalization in these patients (Englund et al., [@B66], [@B61]; Fisher et al., [@B72]).

Respiratory viral infections include RNA viruses such as paramyxoviruses (RSV, parainfluenza, HMPV), orthomyxoviruses (influenza), picornaviruses (rhinovirus), and coronaviruses, as well as DNA viruses such as adenovirus, bocavirus, and polyomaviruses (Whimbey et al., [@B223], [@B225]; Englund et al., [@B66]; Kim et al., [@B118]). These RNA viruses are among the most common causes of respiratory infection in immunocompromised patients (Whimbey et al., [@B225]; Hirsch et al., [@B102]) (Table [1](#T1){ref-type="table"}). Although the annual activity of these viruses is variable, distinct patterns have been described. They cause seasonal outbreaks, and most are predominantly seen during the winter (Whimbey et al., [@B223], [@B225]; Kim et al., [@B118]).

###### 

Taxonomy and virologic properties of the major human respiratory RNA viruses[^a^](#TN1){ref-type="table-fn"}.

  **Virus**                     **Family**           **Size (nm)**   **RNA genome**     **Envelope**   **Genetic or antigenic types**
  ----------------------------- -------------------- --------------- ------------------ -------------- --------------------------------------------------------------------
  Respiratory syncytial virus   *Paramyxoviridae*    120--200        Linear ss(--)      Yes            Antigenic subgroups A and B with 10 A genotypes and 13 B genotypes
  Influenza virus               *Orthomyxoviridae*   80--120         Segmented ss(--)   Yes            3 antigenic types (A, B, C); A has 3 HA and 2 NA human subtypes
  Parainfluenza virus           *Paramyxoviridae*    120--180        Linear ss(--)      Yes            4 serotypes (1, 2, 3, 4); subtypes 4a and 4b
  Metapneumovirus               *Paramyxoviridae*    120--180        Linear ss(--)      Yes            Subtypes A and B; subgroups A1/A2 and B1/B2, respectively
  Rhinoviruses                  *Picornaviridae*     20--27          Linear ss(+)       No             \>100 antigenic types
  Coronaviruses                 *Coronaviridae*      80--160         Linear ss(+)       Yes            6 genotypes (229E, OC43, NL63, HKU1, SARS-CoV, MERS-CoV)

*ss(--), single-stranded negative-sense RNA; ss(+), single-stranded positive-sense RNA; HA, hemagglutinin; NA, neuraminidase; SARS-CoV, severe acute respiratory syndrome-coronavirus; MERS-CoV, Middle East respiratory syndrome-coronavirus. Reproduced from Hodinka ([@B103])*.

Clinical presentation can range from asymptomatic viral shedding to severe respiratory distress (Hakim et al., [@B88]; Fisher et al., [@B72]). Severity of disease depends on intrinsic viral factors, as well on patient characteristics including underlying diagnosis and treatment, with myelosuppression and HCT bearing the highest morbidity and mortality (Kim et al., [@B118]; Hakim et al., [@B88]; Fisher et al., [@B72]). Adverse outcomes are far more likely in immunocompromised patients than in non-immunocompromised individuals and include progression to pneumonia, respiratory failure, and increased mortality rates (Kim et al., [@B119]). In immunocompromised adults with cancer, progression to LRTI ranges from 30 to 50%, and for those who develop pneumonia, mortality can be as high as 75% (Hirsch et al., [@B102]; Renaud et al., [@B177]; Chemaly et al., [@B33]; Campbell et al., [@B22]; Hutspardol et al., [@B106]; Chu et al., [@B36]). Mortality associated with respiratory viruses in children undergoing HCT varies, usually ranging between 10 and 14% but can be as high as 30% (Ljungman et al., [@B131]; Luján-Zilbermann et al., [@B135]; Hutspardol et al., [@B106]). Although significantly lower than in adults, mortality remains considerably higher than that for the general population. Long term complications associated with respiratory viral infections, such as airflow obstruction and bronchiolitis obliterans, have developed in HCT and lung transplant recipients (Campbell et al., [@B22]; Chu et al., [@B36]).

A focus of interest has been to determine and assess risk factors for progression to LRTI with the goal to detect patients who might benefit from interventions that could prevent clinical progression. Age, lymphopenia, high-dose total body irradiation and presence of co-pathogens are significant risk factors for progression to LRTI (El Saleeby et al., [@B58]; Waghmare et al., [@B215]; Kim et al., [@B119]). Clinical scores have been developed for adults undergoing HCT and in healthy children with RSV infection to better predict severity (Shah et al., [@B189]; Caserta et al., [@B26]). However, the former has not been validated in children and the latter lacks important features surrounding this particular sub group of patients.

Diagnostic {#s2}
==========

Diagnostic testing for respiratory viruses has evolved tremendously in the past several years. This is equally true for HCT patients as it has been for immunocompetent patients, where the same testing modalities are utilized. Molecular amplification techniques have largely supplanted cell culture as the primary means of detecting and identifying viruses in clinical diagnostic samples (Mahony, [@B139]; Mahony et al., [@B140]). Antigen-based detection is used in some acute care settings, but typically shows inferior sensitivity and specificity compared to molecular methods. PCR is the most common amplification technique, with FDA cleared or approved *in vitro* diagnostic tests available commercially to detect all common respiratory viral pathogens (Caliendo, [@B21]) (Table [2](#T2){ref-type="table"}). These are marketed as single analyte assays (such as tests that detect only influenza A), as assays detecting only a small number of analytes (for example, detecting only influenza and RSV), and as broad-panel test (detecting 12--20 different pathogens) (Rand et al., [@B170]; Hammond et al., [@B95]; Hayden et al., [@B97]; Popowitch et al., [@B167]; Salez et al., [@B182]). Often the latter also include some common bacterial agents of infection. Such molecular tests generally have a high degree of sensitivity and specificity, with a much more rapid time to result compared to culture. Larger, multiplexed panels can be advantageous in an immunocompromised population as even the detection of pathogens without available specific antiviral therapies can have important implications for infection control and potentially for decisions surrounding the time of transplant. Furthermore, symptoms can be atypical, making it difficult to predict the most likely agents of infection with any degree of clinical certainty. Such highly sensitive tests raise numerous questions, however. Despite uncertain clinical significance, the incidence of detectable multi-viral infections tends to be increased using these methods, sometimes with four or more agents detected simultaneously. The advent of molecular testing has also increased the time of detectable viral shedding which is often lengthened in immunocompromised patients, and the risk of spread or recurrence during periods of asymptomatic shedding is unknown. Quantitative methods (as noted elsewhere in this work) may shed light, both on viral dynamics and on the clinical implications of asymptomatic shedding. Such information awaits increased availability of these tests, together with publication of more studies in this high-risk population.

###### 

Laboratory methods for diagnosis of the major human respiratory RNA viruses[^a^](#TN2){ref-type="table-fn"}.

  **Methods**                          **Sensitivity**   **Specificity**   **Test time**   **Clinical usefulness**
  ------------------------------------ ----------------- ----------------- --------------- ----------------------------------------------------------------------------------------------
  **VIRUS CULTURE SYSTEMS**                                                                
  Conventional tube                    Low-moderate      High              3--14 d         Capable of growing any virus; involves considerable time, labor, and resources
  Shell vial or microwell plate        Low-moderate      High              1--3 d          Rapid centrifugation-assisted cultures for select viruses; less sensitive than tube cultures
  **DIRECT ANTIGEN DETECTION TESTS**                                                       
  Immunofluorescence                   Moderate          Moderate-high     1--2 h          Rapid, multianalyte detection; moderately complex and subjective reading
  Immunoassays                         Low-moderate      Moderate-high     ≤ 15 min        Fast and simple to use; amenable to point-of-care testing
  Nucleic acid amplification tests     High              High              15 min−8 h      New reference standard; superior performance characteristics
  Serology                             NA                NA                NA              Not useful for diagnosis; used for research and epidemiologic studies

*d, days; h, hours; min, minutes. Reproduced from Hodinka ([@B103])*.

Several authors have studied the yield and correlation of respiratory samples from upper airway and lower airway in the setting of LRTI. Hakki et al. analyzed 72 paired nasopharyngeal (NP) and bronchoalveolar lavage fluid specimens from immunocompromised adult patients for respiratory viruses. NP samples had a positive and negative predictive value of 86.4 and 94% respectively. In three sets the NP sample was negative and the BAL was positive (Hakki et al., [@B89]). Azadeh et al. report that 20% of patients with an initial negative NP wash had a positive BAL sample, suggesting that a BAL may be valuable when there are concerns for LRTI and the NP wash is negative (Azadeh et al., [@B11]). This has been particularly reported by several groups in the setting of severe pandemic H1N1 influenza infection (Mulrennan et al., [@B151]; Yeh et al., [@B226]; Lee et al., [@B127]).

Susceptibility testing is limited to influenza. Emergence of universal resistance of IV A H1N1 and IV A H3N2 to adamantanes, as well as rapid emergence of oseltamivir resistant IV A H1N1 led to increased efforts to closely monitor drug resistance (Renaud et al., [@B176], [@B171],[@B175]; Okomo-Adhiambo et al., [@B160], [@B159]). Both phenotypic and genotypic assays have developed, but genotypic methods are most commonly used for routine testing to detect neuraminidase inhibitor resistance of influenza viruses in clinical specimens (Hirsch et al., [@B102]; Marjuki et al., [@B141]; Okomo-Adhiambo et al., [@B161]; Laplante and St George, [@B126]; Tamura et al., [@B201]).

Isolation Control Practices {#s3}
===========================

Several strategies have been suggested to decrease the risk of hospital transmission of respiratory viruses. Hand hygiene, screening visitors for respiratory symptoms, education of healthcare personal to avoid caring for patients if they are sick and isolation of patients with respiratory symptoms are among the most widely strategies implemented across institutions (Dykewicz, [@B55]; Tomblyn et al., [@B205]; Engelhard et al., [@B59]; Hirsch et al., [@B102]). Molecular testing has allowed for more rapid detection of viral etiology becoming an important tool to guide prevention practices. Whole genome sequencing---next generation sequencing is emerging as a potent tool to further enhance outbreak investigation and has been successfully applied in rhinovirus, influenza, and RSV (Gilchrist et al., [@B81]; Greninger et al., [@B83]; Kothari et al., [@B123]; Zhu Y. et al., [@B228]; Houlihan et al., [@B105]). A particular challenge in this population is the high proportion of asymptomatic patients with respiratory viral infections and whether isolation in the absence of symptoms is indicated (Raad et al., [@B169]; Waghmare et al., [@B216]). Quantitative methods may aid useful information on determining the infectious risk in these patients.

Patients with respiratory symptoms should be put immediately on contact and droplet isolation. At St Jude we use clinical symptoms and viral etiology to determine isolation strategies. We stop isolation in patients with infections due to rhinovirus, enterovirus, coronavirus, or unidentified etiology after 48 h of resolution of symptoms with no retesting needed. Patients with respiratory infection due to RSV, influenza, HMPV, or HPIV require both resolution of symptoms and a negative test to be taken off isolation.

Treatment {#s4}
=========

Although advances in the treatment of respiratory infections have been made, management of viral infections in this population remains a challenge (Ljungman et al., [@B131]; Casper et al., [@B27]; Chemaly et al., [@B33]; Waghmare et al., [@B216]; Shahani et al., [@B195]). Treatment is primarily supportive and includes, fluid replacement, oxygen for hypoxia and mechanical ventilation if necessary (Meissner, [@B145]; Kou et al., [@B124]). Bronchodilators may provide some benefit (Meissner, [@B145]; Kou et al., [@B124]). Given the significant mortality rate in immunocompromised host, antiviral therapy should be considered when available (Casper et al., [@B27]; Renaud and Englund, [@B173]; Hirsch et al., [@B102]; Waghmare et al., [@B216]; Shahani et al., [@B195]). However, antiviral options are scarce and limited to influenza and, to a lesser extent, RSV (Table [3](#T3){ref-type="table"}) (Casper et al., [@B27]; Chemaly et al., [@B33]; Waghmare et al., [@B216]; Jorquera and Tripp, [@B111]; Shahani et al., [@B195]). In addition, adjunctive therapy such as intravenous immunoglobulin (IVIG) or monoclonal antibodies, such as palivizumab, have shown mixed results (Ghosh et al., [@B80]; de Fontbrune et al., [@B42]; Hirsch et al., [@B102]; Falsey et al., [@B69]). Several antivirals and monoclonal antibodies are at different stages of development for the treatment of respiratory viruses (Table [4](#T4){ref-type="table"}).

###### 

Current approved antivirals for treatment of the major human respiratory RNA viruses.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Virus**                     **Antiviral**                                  **Drug class**           **Dose/Duration**                                             **Side effects**                                   **Resistance**                                                 
  ----------------------------- ---------------------------------------------- ------------------------ ------------------------------------------------------------- -------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Respiratory syncytial virus   Ribavirin                                      Nucleoside analog        Children/Adults: Inhaled Oral                                 2 grams over 2 h TID\                              Bronchospasm Hemolysis, liver and renal toxicity               None reported
                                                                                                                                                                      Loading dose of 600 mg\                                                                                           
                                                                                                                                                                      200 mg TID on day 1\                                                                                              
                                                                                                                                                                      400 mg TID on day 2\                                                                                              
                                                                                                                                                                      Then maximum\                                                                                                     
                                                                                                                                                                      30/mg/kg/day                                                                                                      

  Influenza virus               Oseltamivir                                    NAI                      Adults\                                                       75 mg PO twice per day\                            Nausea, vomiting                                               Influenza A(H1N1) virus strains H275Y substitution leads to resistance
                                                                                                        Children       \>40 kg\                                       75 mg PO twice per day\                                                                                           
                                                                                                        ≥ 12             24--40 kg\                                   60 mg PO twice per day\                                                                                           
                                                                                                        months         16--23 kg\                                     45 mg PO twice per day\                                                                                           
                                                                                                                          15 kg or less                               30 mg PO twice per day                                                                                            

                                                                                                        Children\                                                     3 mg/kg/dose PO twice per day                                                                                     
                                                                                                        \< 12 months                                                                                                                                                                    

                                                                                                        Longer duration (10 days) for immunocompromised individuals                                                                                                                     

                                Zanamivir                                      NAI                      Adults                                                        Two 5-mg inhalations (10 mg total) twice per day   Bronchospasm, diarrhea, nausea, headache, dizziness            Influenza A (H1N1) with both an H275Y and E119D or E119G. NA substitution lead to resistance

                                                                                                        Children (age, 7 years or older)                              Two 5-mg inhalations (10 mg total) twice per day                                                                  

                                Peramivir                                      NAI                      Adults                                                        600 mg single dose (IV)                            Neutropenia, diarrhea                                          Influenza A(H1N1) virus strains with H275Y substitution leads to resistance

                                                                                                        Children (age, 29 days of life or older)                      N/A                                                                                                               

                                                                                                        Longer duration (5 days) for immunocompromised individuals                                                                                                                      

                                Amantadine[^\*^](#TN3){ref-type="table-fn"}    M2 inhibitors            ≥10 years and ≥40 kg\                                         100 mg PO twice daily\                             Cardiac, neurologic and gastrointestinal events; neutropenia   High prevalence of resistance in all Influenza A (H3N2) and (H1N1) pdm09 Not active against Influenza B
                                                                                                        ≥10 years and \<40 kg\                                        5 mg/kg/day PO in 2 doses\                                                                                        
                                                                                                        1--9 years.                                                   5 mg/kg/day PO in 2 doses                                                                                         

                                Rimantadine[^\*^](#TN3){ref-type="table-fn"}   M2 inhibitors            ≥10 years/Adolescents\                                        5 mg/kg/day PO in 2 doses\                         Neurological and cardiac events                                Same as for Amantadine
                                                                                                        1 − 9 years                                                   6.6 mg/kg/day PO in 2 doses                                                                                       

                                Baloxavir marboxil                             Endonuclease inhibitor   ≥ 12 years and ≥80 kg\                                        80 mg PO once\                                     Diarrhea, bronchitis                                           Influenza A (H3N2) and (H1N1) with substitutions I38F/M/F show reduced susceptibility.
                                                                                                        ≥12 years and \<80 kg.                                        40 mg PO once                                                                                                     

  Parainfluenza virus           None licensed                                                                                                                                                                                                                                           

  Metapneumovirus               None licensed                                                                                                                                                                                                                                           

  Rhinovirus                    None licensed                                                                                                                                                                                                                                           

  Coronavirus                   None licensed                                                                                                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Not recommended given high prevalence of resistance for influenza A strains. Adapted from Englund et al. ([@B64], [@B63]), Knight et al. ([@B121]), Boeckh et al. ([@B17]), Casper et al. ([@B27]), Renaud et al. ([@B176], [@B171],[@B174]), Hirsch et al. ([@B102]), Waghmare et al. ([@B216]), Shahani et al. ([@B195]), AAP ([@B3]), and Hayden et al. ([@B96])*.

###### 

Antivirals and monoclonal antibodies on the pipeline for treatment of the major human respiratory RNA viruses.

  **Virus**                     **Antiviral**                   **Drug class/mechanism of action**                         **Route of administration**   **Company**
  ----------------------------- ------------------------------- ---------------------------------------------------------- ----------------------------- --------------------------
  Respiratory syncytial virus   ALS-8176 (a.k.a Lumicitabine)   Nucleoside analog                                          Orally                        Alios BioPharma
                                                                RNA-dependent RNA-polymerase (RdRp)                                                      
                                GS-5806 (a.k.a Presatovir)      Fusion inhibitor[^\*^](#TN4){ref-type="table-fn"}          Orally                        Gilead
                                VP-14637 (aka MDT-637)          Fusion inhibitor[^\*^](#TN4){ref-type="table-fn"}          Inhaled                       ViroPharma
                                JNJ-53718678                    Fusion inhibitor                                           Orally                        Johnson & Johnson
                                BTA-C585 (a.k.a Enzaplatovir)   Fusion inhibitor[^\*^](#TN4){ref-type="table-fn"}          Orally                        Vaxart
                                AK-0529                         Fusion inhibitor                                           Orally                        Ark Biosciences
                                RSV604                          Nucleoprotein inhibitor                                    Orally                        Astra Zeneca
                                ALN-RSV01                       Nucleoprotein inhibitor                                    Orally                        AlnylamPharmaceuticals
                                Palivizumab (Synagis)           Monoclonal antibody                                        Intramuscular                 MedImmune
                                REGN2222 (a.k.a Suptavumab)     Monoclonal antibody                                        Intramuscular                 RegeneronPharmaceuticals
                                MEDI8897                        Monoclonal antibody                                        Intramuscular                 MedImmune
                                ALX-0171                        Monoclonal antibody                                        Inhaled                       Ablynx
  Influenza virus               DAS181 (a.k.a.Fludase)          Targets the Viral Receptor (Sialic Acid)                   Inhaled                       Ansun BioPharma
                                Laninamivir (CS-8958)           Long-acting neuraminidase inhibitors                       Inhaled                       Biota
                                Favipiravir (T705)              Nucleotide analogRNA polymerase                            Orally                        Toyama Chemical
                                JNJ-63623872 (a.k.a VX-787)     Nonnucleoside inhibitor                                    Orally                        Janssen
                                Nitazoxanide (a.k.a NT-300)     ThiazolidesInhibits the maturation of influenza virus HA   Orally                        Romark Laboratories
                                MEDI8852                        Monoclonal antibody                                        Intravenous                   AstraZeneca
                                VIS410                          Monoclonal antibody                                        Intravenous                   Visterra
  Parainfluenza virus           DAS181 (a.k.a.Paradase)         Targets the Viral Receptor (Sialic Acid)                   Inhaled                       Ansun BioPharma
  Human Metapneumovirus         MAb 338                         Monoclonal antibody                                        Intravenous                   Medimmune
  Human Rhinovirus              Vapendavir                      Binds to the RhV VP1 capsid                                Orally                        Aviragen Therapeutics

*inhibit RSV fusion through a similar mechanism, and RSV variants exhibiting drug resistance have displayed cross-resistance to these inhibitors. Adapted from (Douglas et al. ([@B53]); Triana-Baltzer et al. ([@B208]); Boeckh and Englund ([@B18]); Kiso et al. ([@B120]); Sleeman et al. ([@B196]); Watanabe et al. ([@B220]); Guzmán-Suarez et al. ([@B85]); Moss et al. ([@B150]); Adedeji et al. ([@B7]); Matz ([@B143]); Clark et al. ([@B37]); DeVincenzo et al. ([@B51], [@B50]); Rossignol ([@B179]); Byrn et al. ([@B20]); Battles et al. ([@B12]); Waghmare et al. ([@B216]); Coates et al. ([@B38]); Heylen et al. ([@B101]); Jorquera and Tripp ([@B111]); Kim et al. ([@B117]); Koszalka et al. ([@B122]); Mejias et al. ([@B146]); Roymans et al. ([@B180]); Shahani et al. ([@B195]); Heo ([@B99]); Omoto et al. ([@B162]); Rossey et al. ([@B178]), and Stevens et al. ([@B199])*.

RSV {#s5}
===

RSV is a single stranded, negative-sense RNA virus within the family *Paramyxoviridae*. Its genome transcribes to produce 11 proteins: NS1, NS2, N, P, M, SH, G, F, M2-1, M2-2, and L (Papenburg and Boivin, [@B164]; Tregoning and Schwarze, [@B206]). The attachment glycoprotein (G) and the fusion (F) glycoprotein are the two major glycoproteins on the surface of RSV. They control the initial phases of infection (McLellan et al., [@B144]). F protein is the main target for antiviral development. However, both G and F glycoproteins are targeted by neutralizing antibodies during natural infection (Capella et al., [@B23]; Melero et al., [@B147]; Tian et al., [@B203]). There is a single antigenic type of RSV, divided into two subgroups, A and B. Usually one of these groups predominates on an epidemic. The significant of the variants and its role on disease severity is not well-understood (Hall et al., [@B92]; Walsh et al., [@B218], [@B219]; Devincenzo, [@B46]).

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in children. Premature infants, infants with cardiac disease, and severely immuno-compromised patients experience increased morbidity and mortality (Domachowske and Rosenberg, [@B52]; DeVincenzo et al., [@B47]; Devincenzo, [@B46]; Hall et al., [@B93], [@B91]). RSV infections resembles the same seasonal pattern in patients with HCT and/or other hematological diseases and its occurrence is a result of increased risk of infection from the community, household contacts, and nosocomial transmission (Hall, [@B90]; Hall et al., [@B93], [@B91]). In a single center study, Hakim and colleagues determined the epidemiology of respiratory viruses on children with acute lymphoblastic leukemia. They reported that RSV was the second most common respiratory accounting for 31% of all episodes of respiratory viral infections (Hakim et al., [@B88]). Hirsch et al. described that RSV infection in pediatric patients with acute myeloid leukemia can be up to 2.2% (Hirsch et al., [@B102]). Fisher et al found that RSV was the third most common respiratory viral infection in pediatric patients undergoing HCT after RhV and PIV, with an all cause fatality rate of 10% (Fisher et al., [@B72]).

RSV LRTI is associated with increased rate of hospitalization and mortality. Several risk factors have been described for RSV LRTI (Seo et al., [@B185]; Chemaly et al., [@B33]; Kim et al., [@B119]). El-Saleeby and colleagues found that younger age and lymphopenia were significantly associated with RSV LRTI in children (El Saleeby et al., [@B58]). In Hakim\'s study a lower nadir ALC also associated with RSV LTRI (Hakim et al., [@B88]). In fact, RSV, as compared to other virus, was more likely to be associated with LRTI, accounting for 58% of all viral episodes of LRTI (Hakim et al., [@B88]). Age, neutropenia, lymphocytopenia, graft-vs.-host disease, use of myeloablative conditioning regimens, use of corticosteroids, a recent HCT, and pre-engraftment are the most significant risk factors included in an index developed by investigators at University of Texas MD Anderson Cancer Center to categorize patients into prognostic risk groups (Shah et al., [@B189]). Waghmare et al. explored several risk factors for RSV mortality in patients undergoing HCT with RSV infection, including the presence of RSV viremia. This was present in one third of the patients after development of LRTI. While neutropenia and mechanical ventilation were significantly associated with RSV viremia, no effect from lymphopenia or steroids use was observed. In this cohort viremia was independently associated with mortality. Treatment with aerosolized ribavirin was associated with improved outcomes, including decrease overall mortality and mortality due to respiratory failure (Waghmare et al., [@B215]).

Attempts to correlate viral load with RSV disease severity have yielded mixed results (Devincenzo, [@B46]; DeVincenzo et al., [@B49]; Gerna et al., [@B79]; Franz et al., [@B76]; El Saleeby et al., [@B57]; Walsh et al., [@B219]). On one hand, DeVincenzo et al. noted that patients that were intubated had higher viral load than those who were not, and that higher viral load was associated with longer stayed in the hospital (Buckingham et al., [@B19]; DeVincenzo and Buckingham, [@B48]; DeVincenzo et al., [@B49]). However, other studies have not found such association (Gerna et al., [@B79]; Franz et al., [@B76]; Lukens et al., [@B136]). Fuller et al. reported an association of viral load and disease severity in patients under 5 years of age but not in older patients (Fuller et al., [@B77]). The inconsistency of results may be due to technical difficulties of precisely quantifying virus load at a mucosal surface, or perhaps optimal analysis may require sampling over several days. At St. Jude, we have developed a droplet digital PCR assay to quantify RSA A and RSV B in respiratory specimens. Initial clinical validation was performed with 73 samples from 19 patients with RSV infection. RSV viral load was significantly higher in febrile patients \<5 years old, whereas no statistical difference was noted with older patients. Patients who presented with either cough or nasal congestion had significantly higher viral load when compared to those who did not. Patients presenting with all 3 signs and symptoms had higher viral load when compared to those that only presented with one symptom. Eight patients with RSV infection were treated with Ribavirin. Seven of them received inhaled ribavirin and one received IV ribavirin since the patient was on mechanical ventilation. Viral load upon completion of treatment was significantly reduced (Data not published). Viral load testing for RSV is not widely available for clinical diagnostic use, and no FDA-approved methodology is currently on the market.

Ribavirin is a nucleoside analog that resembles guanosine and acts by inhibiting the dehydrogenase enzyme impairing the synthesis of guanosine triphosphate leading to reduce cellular deposits of guanidine necessary for viral growth (Shahani et al., [@B195]). Initiation and elongation of RNA is hampered impeding viral protein synthesis (Knight et al., [@B121]; Chemaly et al., [@B33], [@B30]). Aerosolized ribavirin is the only FDA-approved treatment of severe RSV-LRTIs in hospitalized infants and young children with underlying compromising conditions (prematurity, cardiopulmonary disease, or immunosuppression) (Chemaly et al., [@B33], [@B30]; Waghmare et al., [@B216]). Furthermore, ribavirin-based antiviral therapy is recommended by European guidelines for leukemia patients and HCT recipients at high risk of complications (Hirsch et al., [@B102]).

Shah et al. performed a systematic review based mainly on retrospective studies and found that ribavirin-based therapy was associated with a significant decrease in progression from URTIs to LRTIs. Furthermore, ribavirin alone or in combination with immunomodulatory therapy improved mortality rates when compared to no therapy in adult HCT recipients (Shah and Chemaly, [@B194]). This topic has recently gained a lot of interest given the increase in price of inhaled ribavirin from \$6105 per day in January 2013 to \$29,953 per day, based on average whole- sale price (Chemaly et al., [@B30]). As a consequence of this rise, a 5-day and a 10-day treatment course would cost \$149,765 and \$299,530 respectively. However, the oral formulation is \~\$25 per day depending on dosing strategy (Chemaly et al., [@B30]; Waghmare et al., [@B216]). Some authors suggest that the oral formulation is not effective given low achievable plasma concentrations (Waghmare et al., [@B216]). Other studies show benefit of using oral ribavirin for adult patients with RSV infection (Damlaj et al., [@B41]; Foolad et al., [@B74], [@B73]; Pasikhova et al., [@B165]). These unanswered questions are important given the difference in cost between the two formulations (Shah et al., [@B190]).

Adjuvant therapy for RSV infection has also been controversial. Various other therapies such as intravenous immunoglobulin (IVIG), RSV hyperimmunoglobulin, and palivizumab, have been used for treatment (Shah and Chemaly, [@B194]; Shah et al., [@B191]; Waghmare et al., [@B216]; Shahani et al., [@B195]). Animal models and initial studies showed benefits of ribavirin plus RSV hyperimmunoglobulin compared to ribavirin alone (Gruber et al., [@B84]; Whimbey et al., [@B224]; Ottolini et al., [@B163]; Ghosh et al., [@B80]; Falsey et al., [@B69]). However, production of RSV IVIG has since been discontinued. In adult HCT recipients with RSV pneumonia, uncontrolled studies suggested that use of combination therapy with ribavirin and IVIG improved survival (Whimbey et al., [@B224]; Ghosh et al., [@B80]). However, combined use of ribavirin and IVIG has not been supported by a randomized trial. In forty allogenic HCT recipients with RSV infection, palivizumab failed to reduce progression to LRTI or mortality (de Fontbrune et al., [@B42]). Given the questionable efficacy and high cost of palivizumab (Ambrose and McLaurin, [@B9]), routine use has been discouraged; and practices vary widely among institutions.

At our institution, ribavirin is recommended for treatment of RSV URTI or LRTI in patients \<2 years old with ALC below 300, or in patients of any age with an ALC below 100 who have a diagnosis of AML or relapsed or high risk ALL, those undergoing HCT or have pre-existing severe heart or lung disease (Figure [1](#F1){ref-type="fig"}). We do not use palivizumab as part of treatment, and only consider IVIG if total Ig is below 400 mg/dl. Other antivirals against RSV are at different stages of development (Table [4](#T4){ref-type="table"}) (Jorquera and Tripp, [@B111]).

![Institutional decision tree used at St Jude for inhaled Ribavirin therapy based on risk factors of patients infected with RSV.](fmicb-09-03097-g0001){#F1}

Palivizumab has been proven effective in reducing severe RSV infection in premature infants and children with chronic lung disease (AAP, [@B1],[@B2]). Although efficacy of palivizumab has not been assess in randomized trials in immunocompromised, prudent use of palivizumab in these population may be indicated. Kassis et al. described successfully control of a nosocomial outbreak of RSV in a bone marrow transplant unit where use of palivizumab reduced transmission of RSV in high risk group patients (Kassis et al., [@B115]).

At St. Jude, Palivizumab is administered in 5 monthly doses (November-March) to all patients with AML, SCID, or HCT recipients (including pre-HCT conditioning) who are ≤ 24 months of age and patients ≤ 12 months of age with a diagnosis of acute lymphoblastic leukemia. Other patients ≤ 24 months of age who are receiving intensive, immunosuppressive chemotherapy during the RSV season are considered for prophylaxis on a case by case basis.

Influenza {#s6}
=========

Human influenza viruses (IVs) are members of the family *Orthomyxoviridae* and belong to three genera that contain single antigenically distinct species of the same name: influenza A, influenza B, and influenza C. They have a segmented, single stranded, negative sense RNA genome (Nicholson et al., [@B154]). The three IVs types are distinguished by antigenic differences in their nucleoprotein and matrix protein. The two main surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA) are critical in the replication cycle and pathogenesis of IVS (Nicholson et al., [@B154]).

The seasonal prevalence of influenza infections in immunocompromised patients, closely parallels the community wide prevalence (Appiah et al., [@B10]; Bednarska et al., [@B15]). The incidence of influenza in transplant recipients is low. However, influenza infection remains a significant cause of morbidity and mortality in these patients (Weigt et al., [@B222]). The incidence in HCT recipients ranges from 1 to 3% (Nichols et al., [@B153]). Hakim et al. found that influenza was the most common virus pediatric patients with acute lymphoblastic leukemia (ALL), accounting for 38% of respiratory infections. In this cohort, the majority of patients presented with URTI, and only 6 had evidence of progression to LRTI. Of those, 3 had 2009 pandemic H1N1 influenza A virus, and one had RSV and influenza B virus co-infection, while the remaining 2 patients had influenza A virus that was not subtyped (Hakim et al., [@B88]).

The clinical presentation of influenza does not differ considerably from that described in the general population. URTI symptoms consist of rhinitis and cough. Fever is usually seen in patients with pneumonia (Chemaly et al., [@B31]; Kumar et al., [@B125]). Less frequently, patients can present with gastrointestinal and neurological symptoms (Ison and Hayden, [@B108]; Peck et al., [@B166]). Risk factors associated with severity of infection and progression to LRTI have been described, including lymphopenia, steroids use, and delayed antiviral therapy (Ljungman et al., [@B131], [@B130]; Martino et al., [@B142]; Chemaly et al., [@B31]; Khanna et al., [@B116]; Choi et al., [@B35]). Initiation of antiviral treatment within 48 h of symptoms has been associated with improved outcomes (Nichols et al., [@B153]; Choi et al., [@B35]; Espinosa-Aguilar et al., [@B68]). Tantawi et al. reported 90 children and adolescents with different cancer types who presented with LRTIs necessitating hospital admission. Respiratory viruses were identified in 37.7% of the patients, the majority with hematological malignancies. Influenza were the most common virus associated with hospital admission (influenza A 47%, influenza B 12%). All patients admitted to the ICU had bacterial co-infection. Those who received oseltamivir had a less severe clinical picture (Tantawy et al., [@B202]).

Respiratory complications, such as mechanical ventilation are associated with mortality in immunocompromised patients with influenza infection. The latter ranges from 6 to 28% and can be related to direct viral pathogenesis or to superimposed bacterial infections (Ljungman et al., [@B131]; Nichols et al., [@B153]; Choi et al., [@B35]; Renaud and Campbell, [@B172]; Fisher et al., [@B72]).

In pediatric cancer patients, antiviral treatment should be initiated as early as possible, even if patients have been symptomatic for over 48 h, since there may be benefits even with delayed therapy (AAP, [@B3]). While Influenza B is inherently resistant to M2 inhibitors (amantadine and rimantadine), influenza A has become resistant overtime. Hence, their use is limited. Neuraminidase inhibitors (NAIs), such as oseltamivir, zanamivir, and peramivir are now first line for prophylaxis and treatment of influenza A and B (Casper et al., [@B27]; Fiore et al., [@B71]; Chemaly et al., [@B33]). Oseltamivir is given by mouth, and its main side effects are nausea, vomiting and diarrhea. Inhaled zanamivir can cause bronchospasm, so it should be used cautiously in in patients with chronic lung disease. Intravenous zanamivir is available for compassionate use only. Peramivir is the only NAI approved for IV use (Ison and Hayden, [@B108]; Louie et al., [@B133],[@B134]; Ison, [@B107]). Studies comparing oseltamivir to peramivir have shown similar outcomes. However, the efficacy and safety of peramivir in immunocompromised patients needs further assessment (de Jong et al., [@B43]).

Most mutations conferring resistance to NAIs, such as H275Y in pandemic influenza A H1N1, do not lead to resistance in zanamivir, and its inhaled formulation has been successfully used to treat these patients (Renaud et al., [@B171]; Fraaij et al., [@B75]; Waghmare et al., [@B216]). This is especially important, since immunocompromised patients are at increased risk of developing resistant mutants (Couturier et al., [@B40]; Renaud et al., [@B176], [@B171],[@B174]; Carr et al., [@B25]; Hamada et al., [@B94]; Fraaij et al., [@B75]). Combination therapy has poorly been studied and has not shown benefits. Some experts have recommended increased dosing of oseltamivir due to concerns of poor absorption in patients with mucositis or graft vs. host disease. However, the benefits of such intervention have not been conclusively demonstrated (Casper et al., [@B27]; Watcharananan et al., [@B221]). Length of therapy remains controversial. Given the median time to progression to LRTI and the potential for recurrence, longer treatment courses (10 days) have been suggested in this population (Khanna et al., [@B116]; Waghmare et al., [@B216]).

Endonuclease inhibitors are a new class of antiviral drugs (Clark et al., [@B37]; Byrn et al., [@B20]). Phase III development of Baloxavir marboxil (Xofluza, Shionogi & Co Ltd) is underway in the USA, EU and other countries (Heo, [@B99]; Omoto et al., [@B162]). Xofluza was approved in Japan on February 2018 and has recently been approved in the USA as single oral dose for the treatment of influenza A or B virus infection of patients 12 years of age and older (FDA, [@B70]). The main side effects described have been diarrhea and bronchitis. Amino acid substitutions to the endonuclease active site (I38F/T) have shown reduce susceptibility for Influenza A (H3N2) and (H1N1) strains (Hayden et al., [@B96]). Further studies need to be done to determine whether a single dose would be appropriate for immunocompromised patients.

Early diagnosis and isolation precautions are critical in preventing transmission. Post-exposure antiviral chemoprophylaxis should be given to any immunocompromised patient who comes in close contact with proven or suspected cases during the infectious period of the case (Fiore et al., [@B71]). The infectious period for persons with influenza is estimated to range from 1 day before up to 7 days after development of symptoms (Nicholson et al., [@B154]). If a patient comes into contact with a case in an immunocompetent host whose illness started more than 7 days prior, then chemoprophylaxis is not necessary. However, infants and immunocompromised patients shed the virus and remain contagious for a longer period. Post-exposure chemoprophylaxis should last up to 7 days after the last known exposure to influenza.

All immunocompromised patients 6 months of age or older should be vaccinated as soon as possible with the seasonal influenza vaccine (Ljungman, [@B129]; Rubin et al., [@B181]). Although its immunogenicity in immunocompromised patients is variable, and vaccine response is lower than in the general population, some studies show that when vaccinated patients get influenza the severity of infection is less that that compared to unvaccinated patients (Engelhard et al., [@B60]; Machado et al., [@B137]; Issa et al., [@B109]; Beck et al., [@B14]). High-dose trivalent inactivated influenza vaccine elicited a more robust immune response in children with cancer when compared to standard-dose vaccine (Hakim et al., [@B87]). At our institution 2 doses of influenza vaccination are recommended, administered at least 28 days apart. Vaccination of family members and health care providers is also an important measure to prevent influenza infection in these patients (Carr et al., [@B24]; Hakim et al., [@B87]; Sykes et al., [@B200]).

Parainfluenza {#s7}
=============

Parainfluenza viruses (PIVs) belong to the family *Paramyxoviridae* and have a structure similar to that of RSV with a negative sense, single-stranded RNA genome that encodes six common viral proteins. Hemagglutinin-neuraminidase (HN) and F glycoprotein promote viral attachment and fusion of the viral and host cell membranes (Hall, [@B90]; Henrickson, [@B98]). At present, 5 serotypes of Human PIVs (HPIVs) have been recognized: HPIV-1, HPIV-2, HPIV-3, HPIV-4a, and HPIV-4b. They differ in their frequency of occurrence, spectrum of clinical disease and epidemic patterns (Henrickson, [@B98]). PIV3 is the most common serotype producing infections. Infections can occur at any time during the year. However, during spring and summer there is a peak of activity (Hall, [@B90]; Henrickson, [@B98]).

A recent multicenter study aiming to define the epidemiology and outcomes of respiratory virus infection in pediatric HCT recipients showed PIV as the second most common virus. In this cohort RVI was associated with an all-cause case fatality rate of 11 and 8% of patients with HPIV infection died (Fisher et al., [@B72]). A large retrospective study of 1,554 children diagnosed with cancer found that PIV was the most common respiratory virus with an incidence of 54% (74/137). Median age was 3.9 years and 30% of the patients were HCT recipients (Maeng et al., [@B138]). Most of the patients presented with URTI and 20% of them progressed to LRTI with a median of 4 days from onset of symptoms (Maeng et al., [@B138]). Hakim et al found that HPIV was the third most common viral infections in patients with ALL. Unlike RSV, patients with HPIV in this cohort were more likely to present with URTI (Hakim et al., [@B88]). Neutropenia, lymphopenia, coinfection, and use of steroids have been described as risks factors for progression (Srinivasan et al., [@B197],[@B198]; Ustun et al., [@B211]; Seo et al., [@B188]). LRTI was significantly associated with mortality, between 5 to 31 days from initial diagnosis. The overall mortality rate in this cohort was 23% and no differences were observed when comparing HCT recipients with non-HCT recipients (Maeng et al., [@B138]). However, other studies reported mortality rates up to 46% (Nichols et al., [@B152]; Shah et al., [@B192]).

There is currently no antiviral approved for the treatment of HPIV. Ribavirin has been used anecdotical in several cases and has not impacted clinical outcomes, including progression to LRTI and mortality (Chemaly et al., [@B32]; Renaud and Englund, [@B173]). The use of IVIG has not improved survival of HCT recipients with PIVs infections (Knight et al., [@B121]; Shah et al., [@B191]; Chemaly et al., [@B33]; Waghmare et al., [@B216]; Shahani et al., [@B195]).

PIV infection has been linked to bronchiolitis obliterans syndrome (BOS) (Vilchez et al., [@B214], [@B213]; Erard et al., [@B67]). Treatment alternatives for BOS are limited, in part due to the lack of understanding of its pathogenesis. Furthermore, BOS limits long term survival in these patients, highlighting the importance of prevention of PIVs infection in these patients (Chaparro et al., [@B29]; Erard et al., [@B67]).

Although several hospital outbreaks have been reported, nosocomial transmission has been significantly reduced by implementing isolation, hand hygiene, and disinfection of surfaces. There are currently no licensed vaccines for PIVs. Live attenuated PIV vaccines are under development and preliminary results from phase 1 trials suggest that they are safe and immunogenic (Karron et al., [@B113],[@B114]; Adderson et al., [@B6]).

HMPV {#s8}
====

Human metapneumovirus (HMPV) is a single stranded, negative sense RNA enveloped virus from the family *Paramyxoviridae*. The genomic organization is similar to that of RSV with the exception that there is no NS-1 or NS-2. The virus attaches to and enters the host cell through the G and F protein. There are two major subtypes (A and B) composed of subgroups A1/A2 and B1/B2 (Papenburg and Boivin, [@B164]; Schildgen et al., [@B184]).

MPV incidence in immunocompromised hosts has been reported to be as high as 40%. The incidence in those with hematological malignancies did not differ compared to HCT recipients. Although no specific risk factor was described in the included studies, incidence in adult patients was slightly higher than in children (Shah et al., [@B193]). Hakim et al. found that 10% of all acute respiratory infections with an identified virus in children with ALL was due to HMPV. Of these, only one patient developed LRTI (Hakim et al., [@B88]).

HMPV may cause URTI or LRTI in immunocompromised patients. Asymptomatic viral shedding has been described. Patients usually present with nasal congestion, cough, sore throat, or fever. However, once LRTI develops, patients can present with progressive pneumonia, hypotension, and shock (Kamboj et al., [@B112]; Hoppe et al., [@B104]; Samuel et al., [@B183]; Seo et al., [@B186]; El Chaer et al., [@B56]).

A recent article of 181 HMPV infections reported that the vast majority of infections are in patients with hematological malignancies or recipients of HCT. Most of the patients had a community acquired infection and 61% presented with URTI. Of those who presented with LRTI, 25% had progression from URTI. The incidence of LRTI in this review was 34% (El Chaer et al., [@B56]). Risk factors associated with LRTI were use of steroids, low lymphocyte count and, early onset of infection after HCT. LRTI was significantly associated with mortality, which ranged from 0 to 17% in most studies, but can be as high as 43% (Renaud et al., [@B177]; Shah et al., [@B193]; Pasikhova et al., [@B165]).

There is currently no approved antiviral therapy for HMPV. Several attempts have been made to evaluate the role of antiviral therapy with ribavirin for HMPV infections. Considering the limitations on study design given the low number of patients, most of these studies showed no benefits from antiviral therapy with similar mortality rates when compared patients who did not get antiviral treatment (Hoppe et al., [@B104]; Shah et al., [@B193]; Pasikhova et al., [@B165]). Fusion inhibitors and monoclonal antibodies are under development but have not yet reached clinical trials (Table [4](#T4){ref-type="table"}) (Ulbrandt et al., [@B210]; Deffrasnes et al., [@B44]).

Rhinovirus {#s9}
==========

The RhVs belong to the genus *Enterovirus* within the family *Picornaviridae*. They include three genetically distinct groups: A, B, and C. They are single-stranded, positive sense, RNA viruses. The genome encodes one polypeptide that is cleaved in four structural proteins (VP1-4) and 7 non-structural proteins. RhVs are antigenically diverse with over 100 serotypes identified to date (Greenberg, [@B82]; Jacobs et al., [@B110]).

Rhinovirus has been described as the most common respiratory pathogen isolated in immunocompromised children undergoing HCT (Loria et al., [@B132]; Fisher et al., [@B72]), with an incidence as high as 22.3% by day 100 (Milano et al., [@B148]).

The median time for a first positive tests has been reported at 44 days following HCT but can be as early as 2 days and as late as 93 days. There is no apparent seasonality for RhV detection. Prolonged viral shedding is common with a median of 3 weeks (Milano et al., [@B148]). Higher viral load at initial presentation has been significantly associated with prolonged viral shedding (Ogimi et al., [@B158]). In the former study, thirteen percent of patients with RhV infection had no respiratory symptoms at the time of diagnosis. The remaining patients had URT symptoms. Four patients underwent a BAL for concerns of progression to LRTI, of these two died of respiratory failure (Milano et al., [@B148]). These results agreed with a study from Seo et al looking at 697 transplant recipients with rhinovirus infection. In this cohort, eighty one percent of patients presented with URTI. Patients with low monocyte count, oxygen use and steroid dose \> 1 mg/kg/day had significantly increased risk of LRTI. Mortality was higher in those with LRTI (41 vs. 6%) (Seo et al., [@B187]). A multicenter study of respiratory viral infections in pediatric HCT recipient reported an all cause fatality rate of 10% in those patients with RhV infection (Fisher et al., [@B72]).

Pre-transplant rhinovirus detection has been significantly associated with increased mortality at day 100 (Campbell et al., [@B22]). However, Abandhe et al. did not find any differences in ICU admission, length of hospitalization or mortality (Abandeh et al., [@B4]). Currently, treatment of RhV infection consists of supportive care. Antiviral medications for RhV are under investigation (Table [4](#T4){ref-type="table"}).

Coronavirus {#s10}
===========

CoVs are enveloped, positive sense, single stranded RNA viruses belonging to the family *Coronaviridae*. There are six coronaviruses divided in two genera that can infect humans. CoV 229E and NL63 belong to the genus alphacoronavirus and OC43, HKU1, severe acute respiratory syndrome (SARS)-CoV, and Middle East respiratory syndrome (MERS)-CoV are members of the genus betacoronavirus. The genome codes for two non-structural proteins and four structural proteins (van der Hoek, [@B212]; Greenberg, [@B82]).

While CoVs are an important cause of the common cold in the general population, there is limited information on the clinical manifestations in immunocompromised hosts. Milano et al. described the epidemiology and risk factors of CoVs infection among HCT recipients. The cumulative incidence estimated at day 100 was 11.1%. The median time of first detection was 53 days (range, 2--93 days). Seasonal outbreaks were common in the winter with 13 of 22 cases first detected in December through March. The median time of shedding was over 3 weeks (Milano et al., [@B148]).

Ogimi et al. described several risks factors related to prolonged viral shedding, such as higher viral load, use of steroids, and myeloablative conditioning (Ogimi et al., [@B156]). Univariate analysis of potential risk factors showed no significant association of acquisition with patient age, gender, underlying disease risk, stem cell source, CMV serostatus, donor type, acute GVHD, conditioning regimen, or engraftment status. Infection with coronaviruses was not associated with mortality in this cohort (Milano et al., [@B148]). However, another group reported similar mortality rates in HCT recipients to those observed with other viruses such as RSV, influenza virus, and PIV (Ogimi et al., [@B157]).

A recent article from Seattle Children\'s Hospital looked at 85 immunocompromised and 1152 non-immunocompromised children with HCoV infection. Other than median age which was significantly higher for immunocompromised patients, demographic characteristics were similar. Viral co-infection was most commonly seen in non-immunocompromised patients, mostly due to detection of RSV. CoVs strains did not differed between the two groups. The most common clinical presentation was URTI. Younger age, male sex, presence of an underlying pulmonary disorder, and detection of a respiratory co-pathogen, particularly RSV, were associated with an increased likelihood of LRTD or severe LRTD. However, lymphopenia was not associated with more severe disease in this cohort (Ogimi et al., [@B155]).

There is currently no treatment available for coronaviruses. However, current *in vitro* evaluation of HCoV therapy includes investigation of antiviral, as well as human monoclonal antibodies (Pyrc et al., [@B168]; Adedeji et al., [@B7]) (Table [4](#T4){ref-type="table"}).

New Developments in Therapeutics {#s11}
================================

RSV
---

Nucleoside analogs contain a base, or a base analog linked to a ribose-like moiety that can be incorporated by viral polymerases stopping polymerization and inhibiting replication (Jorquera and Tripp, [@B111]). ALS-8176 (a.k.a lumicitabine; Alios BioPharma/Janssen) is a nucleoside analog that inhibits the polymerization function of the L protein by causing immediate chain termination of RNA synthesis (Jorquera and Tripp, [@B111]). In RSV experimentally infected healthy adults, ALS-8176 was significantly associated with more rapid viral clearance, greater reduction of viral load and improvement of clinical symptoms (DeVincenzo et al., [@B50]). Several fusion inhibitors under development are directed at glycoprotein F with the goal of blocking viral entry into cells lining the respiratory tract (Battles et al., [@B12]; Jorquera and Tripp, [@B111]). GS-5806 (a.k.a. Presatovir; Gilead Sciences) is an oral RSV entry inhibitor and functions as an allosteric blocker of the F protein preventing RSV entry by blocking the virus--cell fusion process. Experiments with healthy volunteers with RSV infection showed that treatment with GS-5806 resulted in a reduction of mucus weight, symptom score and viral load (DeVincenzo et al., [@B51]). Similar results were observed with JNJ-53718678 (Johnson & Johnson) (Stevens et al., [@B199]). Finally, targeting the nucleoprotein has gained interest given that is highly conserved and essential for virus assembly (Jorquera and Tripp, [@B111]). RNA interference is a process in which small interfering RNAs (siRNAs) decrease protein production by degrading specific mRNA. Healthy adult volunteers experimentally infected with RSV who received intranasal ALN-RSV01 (Alnylam Pharmaceuticals) showed significant reduction of RSV replication when compared to placebo (DeVincenzo et al., [@B45]).

Monoclonal (mAbs) have been used for prophylaxis of RSV-related hospital admissions in pediatric populations. There are several mAbs targeting different epitopes of F protein under development (Rossey et al., [@B178]). REGN2222 (Suptavumab; Regeneron Pharmaceuticals) is a fully human mAb IgG1 that has proven safety and tolerability in healthy adults. In a recent phase III clinical trial REGN222 failed to prevent RSV infections in infants and the company has discontinued further development. MEDI8897 (MedImmune) is a recombinant human IgG1κ mAb with a modified Fc region that extends more than 3-fold its half-life to 85--117 days after one single dose (Zhu Q. et al., [@B227]). Finally, ALX-0171 (Ablynx) is an inhaled trimeric nanobody that binds the antigenic site II of the F protein and neutralizes RSV A and B. It has shown significant reduction of viral load in infants hospitalized with RSV, when compared to placebo (Ablynx, [@B5]).

Influenza
---------

Fludase (DAS181, Ansun BioPharma), a novel sialidase fusion protein, has shown *in vitro* activity toward all influenza strains isolated to date, such as H5N1, H1N1, H7N9 including those that have shown oseltamivir resistance (Triana-Baltzer et al., [@B207],[@B208]; Moss et al., [@B149]). A phase II clinical trial on healthy volunteers showed safety, tolerability, and effectivity in reducing viral load in the groups receiving DAS181 compared to placebo (Moss et al., [@B150]).

Laninamivir (CS-8958; Biota Pharmaceuticals, Alpharetta, GA, USA) is a long-acting NAI administered via a dry-powder inhaler for the treatment of influenza (Shahani et al., [@B195]). A double-blind, randomized controlled trial in healthy adults demonstrated that a single inhalation of lanimavir octonate is effective for the treatment of influenza. Importantly, lanimavir remains active against oseltamivir-resistant virus (Watanabe et al., [@B220]).

Favipiravir (T705; Toyama Chemical, Tokyo, Japan) is an investigational nucleotide analog that inhibits the viral RNA polymerase of most influenza strains (Kiso et al., [@B120]; Sleeman et al., [@B196]). Two phase 3 studies on adults with uncomplicated influenza have been completed and results are pending (NCT02026349 and NCT02008344).

JNJ-63623872 (VX-787; Janssen Pharma, Titusville, USA) inhibits influenza A replication by a novel mechanism that involves blocking the activity of the polymerase complex.

Nitazoxanide (NT-300; Romark Laboratories, Florida, USA), an antiparasitic agent, has shown broad activity toward influenza A including A(pH1N1) and H7N9, as well as influenza B and strains resistant to oseltamivir (Rossignol, [@B179]; Tilmanis et al., [@B204]). A Phase 2b/3 clinical trial comparing nitazoxanide vs. placebo, showed reduction of clinical symptoms and viral shedding in patients with uncomplicated influenza infection (Haffizulla et al., [@B86]). There are several ongoing trials including a phase 3 to evaluate the role of nitazoxanide for children 12 year of age or older and adults with uncomplicated influenza infection (NCT03336619). mAbs directed toward the highly conserved HA stalk of influenza virus are being developed for both prophylaxis and treatment (Shahani et al., [@B195]).

Parainfluenza
-------------

Paradase (DAS181, Ansun BioPharma) is a novel sialidase fusion protein that prevents viral propagation by cleaving sialic acid from respiratory epithelial cells leading to impair entry of the virus to the cells (Guzmán-Suarez et al., [@B85]; Chalkias et al., [@B28]; Chemaly et al., [@B33]). DAS181 has been given for compassionate use in immunocompromised patients, and has been associated with benefits (Chen et al., [@B34]; Drozd et al., [@B54]; Waghmare et al., [@B217]). Ansun Biopharma has completed a multi-site phase II study comparing DAS181 with placebo in immunocompromised patients with Parainfluenza LRTI requiring oxygen (NCT01644877). In 2017 the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DAS181 for the treatment of lower respiratory tract PIV infection in immunocompromised patients (Biopharma, [@B16]). Phase 3 trials are currently being planned.

Metapneumovirus
---------------

Fusion inhibitors targeting the F protein have demonstrated viral inhibition *in vitro* and in animal models (Deffrasnes et al., [@B44]). A phase 2b study to evaluate the safety, tolerability and pharmacokintetics of ALS-8176 (a.k.a lumicitabine; Alios BioPharma/Janssen) in hospitalized adults with metapneumovirus infection is being planned (NCT03502694). Two mAbs, MAb 338 (Medimmune, Gaithersburg, MD, USA) and human Fab DS7, have prophylactic and therapeutic potential (Ulbrandt et al., [@B210]). However, clinical studies have not yet been performed.

Rhinovirus
----------

Vapendavir (Aviragen Therapeutics, Alpharetta, GA, USA) is an oral antiviral that attaches to the viral capsid preventing release of RNA into the cells. It has activity against RhV type A and B (Shahani et al., [@B195]). Vapendavir has reduced clinical symptoms in asthmatic adults. It was well-tolerated and there were no serious adverse events reported (Matz, [@B143]).

Coronavirus
-----------

Treatment of coronavirus will require broadly active compounds designed to quickly respond to new zoonotic epidemics of pathogenic coronaviruses. There are several steps in coronavirus life cycle where antiviral agents could be implemented (Pyrc et al., [@B168]). Adedeji et al. reported different strategies under development to block viral entry of SARS-CoV (Adedeji et al., [@B7]).

Adoptive T Cell Therapy
-----------------------

Adoptive transfer of specific T cells is a promising approach as technologies for isolation and expansion become widely available (Englund et al., [@B61]; Gerdemann et al., [@B78]; Heslop and Leen, [@B100]; Leen et al., [@B128]; Baugh et al., [@B13]). There are two main limitations to immunotherapy strategies for respiratory viruses. One is that, with the exception of influenza, knowledge of viral immunology is less complete than for CMV and EBV. A second limitation is logistic in that these viruses cause the greatest morbidity in the early post transplantation period, and it may not be feasible to generate CTLs in time to cover this period of high risk. However, Aguayo-Hiraldo et al. successfully expanded and use PIV specific T cells (Aguayo-Hiraldo et al., [@B8]). The same group generated HMPV specific T cells for adoptive transfer in patients after allogeneic HCT (Tzannou et al., [@B209]). Finally, multivirus-specific lymphocytes for the RSV and Influenza have shown promising results (Gerdemann et al., [@B78]).

Conclusion {#s12}
==========

Immunocompromised patients remain vulnerable to respiratory viral infections. Risk of severe LRTI and increased mortality are a common characteristic. Hematological malignancies and HCT recipients bear most of the burden of these viruses. Age, baseline diagnosis, use of steroids, lymphopenia, and early onset after transplant are shared risk factors for LRTI and mortality. Higher viral load has been associated with risk of LRTI in some studies. Early diagnosis can help prevent further spread of these viruses and prompt supportive measures and antivirals when indicated. However, management of these infections remains challenging. Clinical symptoms are not always reliable and progression to LRTI can happen within days of onset of symptoms. In addition, most patients have prolonged viral shedding, making both clinical evolution and molecular testing insufficient to guide length of therapy. Persistently positive tests often lead to concerns of resistant viral strains given the high within host viral diversification that occurs in these patients. There are limited antiviral options available mostly for influenza and to some extent RSV. These problems highlight the need for objective biomarkers that could help guide therapy. Standardization of valid assays to assess viral load will provide unbiased and reproducible measures that could be universally applied to the management of respiratory viral infections in immunocompromised patients. Immune monitoring assays assessing IFN-**γ** producing T cells against specific antigens are gaining interest in the field of systemic viral infection. A set of objective and validated tools related to the host-viral interaction (such as viral load and specific immune response) could lead to parameters that will significantly impact decision making on how to approach and monitor therapeutic options in immunocompromised patients with respiratory viral infections. Having early objective predictors of adverse outcomes could identify children at highest risk for LRTI and death, directing treatment more specifically and in a timelier manner than is currently possible with potential benefits of increased pediatric survival.
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